![Graphic][1] Stroke is a significant cause of mortality and morbidity for which there are limited treatment options. Virtually all drug interventions that have been successful preclinically in experimental stroke have failed to translate to an effective treatment in the clinical setting. In this review, we examine one of the factors likely contributing to this lack of translation, the failure of preclinical studies to consider fully the advanced age and comorbidities (eg, hypertension or diabetes) present in most patients with stroke. Age and comorbidities affect the likelihood of suffering a stroke, disease progression and the response to treatment. Analysing data from preclinical systematic reviews of interventions for ischaemic stroke we show that only 11.4% of studies included an aged or comorbid model, with hypertension being the most frequent. The degree of protection (% reduction in infarct volume) varied depending on the comorbidity and the type of intervention. We consider reasons for the lack of attention to comorbid and aged animals in stroke research and discuss the value of testing a potential therapy in models representing a range of comorbidities that affect patients with stroke. These models can help establish any limits to a treatment’s efficacy and inform the design of clinical trials in appropriate patient populations. [1]: /embed/inline-graphic-1.gif

中文翻译：

---

卒中建模中的合并症和年龄：我们是否仍然没有考虑卒中患者的特征？

![图形][1] 中风是导致死亡和发病的重要原因，治疗选择有限。几乎所有在实验性中风临床前成功的药物干预都未能转化为临床环境中的有效治疗。在这篇综述中，我们检查了可能导致这种缺乏转化的因素之一，即临床前研究未能充分考虑大多数卒中患者的高龄和合并症（例如，高血压或糖尿病）。年龄和合并症会影响中风的可能性、疾病进展和对治疗的反应。分析来自缺血性卒中干预措施的临床前系统评价的数据，我们发现只有 11.4% 的研究包括老年或合并症模型，其中以高血压最为常见。保护程度（梗死体积减少百分比）因合并症和干预类型而异。我们考虑了在卒中研究中缺乏对合并症和老年动物关注的原因，并讨论了在代表影响卒中患者的一系列合并症的模型中测试潜在疗法的价值。这些模型可以帮助确定治疗效果的任何限制，并为适当患者群体的临床试验设计提供信息。[1]：/embed/inline-graphic-1.gif 我们考虑了在卒中研究中缺乏对合并症和老年动物关注的原因，并讨论了在代表影响卒中患者的一系列合并症的模型中测试潜在疗法的价值。这些模型可以帮助确定治疗效果的任何限制，并为适当患者群体的临床试验设计提供信息。[1]：/embed/inline-graphic-1.gif 我们考虑了在卒中研究中缺乏对合并症和老年动物关注的原因，并讨论了在代表影响卒中患者的一系列合并症的模型中测试潜在疗法的价值。这些模型可以帮助确定治疗效果的任何限制，并为适当患者群体的临床试验设计提供信息。[1]：/embed/inline-graphic-1.gif